264 related articles for article (PubMed ID: 36091139)
1. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial.
Guo H; Ding P; Sun C; Yang P; Tian Y; Liu Y; Lowe S; Bentley R; Li Y; Zhang Z; Wang D; Li Y; Zhao Q
Front Oncol; 2022; 12():927781. PubMed ID: 36091139
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
5. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
Zhang Z; Hong ZN; Xie S; Lin W; Lin Y; Zhu J; Yang X; Lin Z; Lin J; Kang M
Ann Transl Med; 2021 Nov; 9(21):1623. PubMed ID: 34926667
[TBL] [Abstract][Full Text] [Related]
8. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.
Chen G; Jin Y; Guan WL; Zhang RX; Xiao WW; Cai PQ; Liu M; Lin JZ; Wang FL; Li C; Quan TT; Xi SY; Zhang HZ; Pan ZZ; Wang F; Xu RH
Lancet Gastroenterol Hepatol; 2023 May; 8(5):422-431. PubMed ID: 36870360
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial.
Tian Y; Yang P; Guo H; Liu Y; Zhang Z; Ding P; Zheng T; Deng H; Ma W; Li Y; Fan L; Zhang Z; Wang D; Zhao X; Tan B; Liu Y; Zhao Q
Int J Surg; 2023 Dec; 109(12):4000-4008. PubMed ID: 37678277
[TBL] [Abstract][Full Text] [Related]
12. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
Zheng Y; Yang X; Yan C; Feng R; Sah BK; Yang Z; Zhu Z; Liu W; Xu W; Ni Z; Beeharry MK; Hua Z; Yan M; Zhu Z; Li C
Eur J Cancer; 2020 May; 130():12-19. PubMed ID: 32171104
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma.
Lv H; Tian Y; Li J; Huang C; Sun B; Gai C; Li Z; Tian Z
Front Oncol; 2022; 12():864533. PubMed ID: 35574384
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.
Zhang Z; Ye J; Li H; Gu D; Du M; Ai D; Chen W; Fang Y; Xu X; Bai C; Zhao K; Zhou G
Front Immunol; 2022; 13():1031171. PubMed ID: 36311804
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study.
Wang X; Huang J; Huang H; Liu Y; Ji C; Liu J
Invest New Drugs; 2023 Aug; 41(4):579-586. PubMed ID: 37368088
[TBL] [Abstract][Full Text] [Related]
17. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study.
Zhang X; Zhang C; Hou H; Zhang Y; Jiang P; Zhou H; Wang L; Zhou N; Zhang X
Transl Oncol; 2023 May; 31():101657. PubMed ID: 36934638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]